First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY

被引:28
作者
Goldberg, Stuart L. [1 ]
Cortes, Jorge E. [2 ]
Gambacorti-Passerini, Carlo [3 ]
Hehlmann, Ruediger [4 ]
Khoury, H. Jean [5 ]
Michallet, Mauricette [6 ]
Paquette, Ron L. [7 ]
Simonsson, Bengt [8 ]
Zyczynski, Teresa [9 ]
Foreman, Aimee [10 ]
Abruzzese, Elisabetta [11 ]
Andorsky, David [12 ]
Beeker, Aart [13 ]
Cony-Makhoul, Pascale [14 ]
Hansen, Richard [15 ]
Lomaia, Elza [16 ]
Olavarria, Eduardo [17 ]
Mauro, Michael J. [18 ]
机构
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, 92 Second St, Hackensack, NJ 07601 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Milano Bicocca, San Gerardo Hosp, Monza, Italy
[4] Heidelberg Univ, Mannheim, Germany
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Ctr Hosp Lyon Sud, Pierre Benite, France
[7] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[8] Uppsala Univ, Uppsala, Sweden
[9] Bristol Myers Squibb Co, Princeton, NJ USA
[10] ICON Plc, San Francisco, CA USA
[11] S Eugenio Hosp, Rome, Italy
[12] Rocky Mt Canc Ctr, Boulder, CO USA
[13] Spaarne Hosp, Hoofddorp, Netherlands
[14] Ctr Hosp Annecy Genevois, Pringy, France
[15] Inst Med, IDGGQ, Kaiserslautern, Germany
[16] Federal Almazov North West Med Res Ctr, St Petersburg, Russia
[17] Imperial Coll London, Hammersmith Hosp, London, England
[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
关键词
TYROSINE KINASE INHIBITORS; CHRONIC MYELOGENOUS LEUKEMIA; 2904 CML PATIENTS; MOLECULAR RESPONSE; RANDOMIZED CML; IMATINIB; MANAGEMENT; RECOMMENDATIONS; SURVIVAL; ADHERENCE;
D O I
10.1002/ajh.24887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Achieving successful outcomes in chronic phase-chronic myeloid leukemia (CP-CML) requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor use and management patterns in patients with CP-CML receiving first-line imatinib (n = 416), dasatinib (n = 418) or nilotinib (n = 408) in the US and 6 European countries in routine clinical practice. Twelve-month follow-up data of 1242 prospective patients (enrolled October 01 2010-September 02 2015) are reported. 81% of patients had baseline comorbidities. Treatment selection was based on perceived efficacy over patient comorbidity profile. There was a predominance of imatinib-treated patients enrolled earlier in the study, with subsequent shift toward dasatinib- and nilotinib-treated patients by 2013/2014. Monitoring for either CyR/MR improved over time and was documented for 36%, 82%, and 95% of patients by 3, 6, and 12 months, respectively; 5% had no documentation of CyR/MR monitoring during the first year of therapy. Documentation of MR/CyR testing was higher in Europe than the US (P < .001) and at academic versus community practices (P = .001). Age <65 years, patients being followed at sites within Europe, those followed at academic centers and patients no longer on first-line therapy were more likely to be monitored by 12 months. SIMPLICITY demonstrates that the NCCN and ELN recommendations on response monitoring have not been consistently translated into routine clinical practice. In the absence of appropriate monitoring practices, clinical response to TKI therapy cannot be established, any needed changes to treatment strategy will thus not be implemented, and long-term patient outcomes are likely to be impacted.
引用
收藏
页码:1214 / 1223
页数:10
相关论文
共 50 条
[41]   Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States [J].
Atallah, Ehab L. ;
Wei, David ;
Latremouille-Viau, Dominick ;
Rossi, Carmine ;
Damon, Andrea ;
Ferreira, Germano ;
Guerin, Annie ;
Jadhav, Kejal .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (03) :178-187.e2
[42]   Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia [J].
Rea, Delphine ;
Mirault, Tristan ;
Cluzeau, Thomas ;
Gautier, Jean-Francois ;
Guilhot, Francois ;
Dombret, Herve ;
Messas, Emmanuel .
HAEMATOLOGICA, 2014, 99 (07) :1197-1203
[43]   A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia [J].
Owen, Carolyn ;
Bence-Bruckler, Isabelle ;
Chamakhi, Ines ;
Toze, Cynthia ;
Assaily, Wissam ;
Christofides, Anna ;
Robinson, Sue .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (06) :303-313
[44]   Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase [J].
Cony-Makhoul, Pascale ;
Gardembas, Martine ;
Coiteux, Valerie ;
Carpentier, Nathalie ;
Pommier, Cecile ;
Violet, Isabelle ;
Quittet, Philippe ;
Berger, Marc G. .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (03) :356-364
[45]   Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis [J].
Sheng, Guangying ;
Chen, Suning ;
Dong, Chaohui ;
Zhang, Ri ;
Miao, Miao ;
Wu, Depei ;
Tan, Seng Chuen ;
Liu, Chao ;
Xiong, Tengbin .
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) :371-381
[46]   Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia [J].
Gugliotta, Gabriele ;
Castagnetti, Fausto ;
Breccia, Massimo ;
Levato, Luciano ;
D'Adda, Mariella ;
Stagno, Fabio ;
Tiribelli, Mario ;
Salvucci, Marzia ;
Fava, Carmen ;
Martino, Bruno ;
Cedrone, Michele ;
Bocchia, Monica ;
Trabacchi, Elena ;
Cavazzini, Francesco ;
Usala, Emilio ;
Rossi, Antonella Russo ;
Bochicchio, Maria Teresa ;
Soverini, Simona ;
Alimena, Giuliana ;
Cavo, Michele ;
Pane, Fabrizio ;
Martinelli, Giovanni ;
Saglio, Giuseppe ;
Baccarani, Michele ;
Rosti, Gianantonio .
HAEMATOLOGICA, 2015, 100 (09) :1146-1150
[47]   Clinical significance of serum prohibitin in chronic myeloid leukemia patients on first-line tyrosine kinase inhibitors [J].
Yassin, Heba A. ;
Azaazi, Mohamed O. ;
Hegab, Hany M. ;
Nabih, Nermine A. ;
Rakha, Nahed M. ;
Naguib, Mary G. .
EGYPTIAN JOURNAL OF HAEMATOLOGY, 2023, 48 (01) :55-57
[48]   Clinical Significance of Serum Prohibitin in Chronic Myeloid Leukemia Patients on First-Line Tyrosine Kinase Inhibitors [J].
Rakha, Nahed Moawad ;
Yassin, Heba A. ;
Azzazi, Mohamed ;
Hegab, Hany M. ;
Nabih, Nermeen A. ;
Naguib, Mary G. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S287-S287
[49]   Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice [J].
Ha, Nghiem B. ;
Trinh, Huy N. ;
Rosenblatt, Lisa ;
Nghiem, Dat ;
Nguyen, Mindie H. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 (02) :169-174
[50]   NilotinibIn the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase [J].
Karly P. Garnock-Jones .
Drugs, 2011, 71 :1579-1590